Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
Go back to Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 64.84 -1.85 (2.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.69 | 52 Week High | $19.98 | |||
| Open | $67.00 | 52 Week Low | $10.52 | |||
| Day High | $67.96 | P/E | N/A | |||
| Day Low | $63.91 | EPS | $-1.45 | |||
| Volume | 909,542 | |||||
